BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 23566679)

  • 1. B-cell targeted therapeutics in clinical development.
    Blüml S; McKeever K; Ettinger R; Smolen J; Herbst R
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S4. PubMed ID: 23566679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depletion and repopulation in autoimmune diseases.
    Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
    Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
    Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell-directed therapy for inflammatory skin diseases.
    Nagel A; Hertl M; Eming R
    J Invest Dermatol; 2009 Feb; 129(2):289-301. PubMed ID: 19148218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.
    Levesque MC
    Clin Exp Immunol; 2009 Aug; 157(2):198-208. PubMed ID: 19604259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell targeted therapies in human autoimmune diseases: an updated perspective.
    Townsend MJ; Monroe JG; Chan AC
    Immunol Rev; 2010 Sep; 237(1):264-83. PubMed ID: 20727041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [B-cell-targeted therapy in the treatment of autoimmune diseases].
    Roll P; Tony HP
    Z Rheumatol; 2009 May; 68(3):255-9. PubMed ID: 19384549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y
    J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biotherapy of auto-immune diseases : past, present and future perspectives].
    Arnaud L; Haroche J; Piette JC; Amoura Z
    Presse Med; 2009 May; 38(5):749-60. PubMed ID: 19303737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.